Can HIV be cured? (how about long term Drug free remission?)

Size: px
Start display at page:

Download "Can HIV be cured? (how about long term Drug free remission?)"

Transcription

1 Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting October 2010 Luxemburg

2 HAART can control HIV, cannot eradicate it Life long treatment Cost Adverse effect Risk for CVD and cancer with age High Active Antiretroviral Therapy (HAART) Adherence Transmission Resistance

3 Growing need Estimated number of people in need of ART 14,6 million (from 10,1 million ) For each person put on HAART = 2-3 person newly infected Therapeutic cure and prophylactic vaccines are rational ways to tackle the epidemic. Source: Towards Universal Access, Progress Report September 2010

4 1996/1997 >3 years of HAART to eradicate HIV?

5 Courtesy of Nicholas Chomont

6 Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun, JCI ; N Tobin, J Virol 2005). HIV integrate in long lived resting memory T cells and persist despite suppressive HAART(TW Chun, Nat. Med 1995, D Finzi, Science ; TW Chun, PNAS 1997). Reservoir cells, like other memory T cells, divide very slowly to maintain the memory of the immune system (A. Bosque and V. Planelles) Courtesy Courtesy of of Nicholas Nicholas Chomont Chomont

7 The Berlin Patient 2007/2008 Gero Hutter

8 HIV patient functionally cured by bone marrow transplant Proof Of Concept Healthy donor with CCR5 mutation Stem cells without CCR5 HIV positive recipient

9 Objectives: Present state of the art research on the control of HIV reservoirs Accelerate research towards a potential HIV cure Highlight the importance of basic science to the HIV response Re-engage the broader HIV community in basic science Strategize to accelerate the translation of findings into clinical practice Provide a networking opportunity for HIV scientists to share ideas and debate with peers

10 2010 IAS Workshop Towards a Cure: HIV Reservoirs and strategies to control them 199 attendees 65 Scholarship recipients 62 abstracts presented 9 invited speakers Clinical Implications of HIV Persistence HIV Reservoirs and Sanctuary Sites HIV Reservoirs and Mucosal Immune Restoration during HAART Mechanisms of Persistence in HIV Infected Individuals The role of the immune system in HIV persistence The role of host factors in HIV persistence Potential therapeutic interventions and how to evaluate them Eradication versus remission: is eradication possible? IAS/ANRS Young Investigator Award on HIV Reservoirs Review in Science: HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals (Trono et al.) Abstract and meeting report Supplement in Journal of the International AIDS Society

11 IAS workshop Towards a Cure AIDS2010 Vienna Brief Overview of ongoing research on HIV reservoirs and mechanisms of persistence

12 Eradicating cure Elimination of all HIVinfected cells HIV RNA < 1 copy/ml Cure Functional cure Long term viral suppression in absence of HAART HIV RNA < 50 copies/ml Remission Inspired by Sharon Lewin, AIDS 2010 Plenary «Strategies for a Cure»

13 How to control /reduce HIV reservoirs? Intensification of HAART (+/- other interventions) Early initiation of HAART (limit viral reservoirs) Improved Drugs (penetrating anatomical compartments) Treatment intensification does not reduce residual HIV-1 viremia in patients on HAART (Dinoso et al PNAS 2009) HIV-1 replication and immune dynamics are affected by Raltegravir intensification of HAART-suppressed subjects (Buzon et al Nat Med 2010) HAART intensification (plus raltegravir and maraviroc) in combination with other interventions (HIV vaccine (DNA+rAd5 or Immunomodulator IL7): Eramune 1& 2 (Katlama/Autran) HAART initiation during acute infection limit the frequency of latently infected cells and preserve HIV specific memory CD4 T cells (Trono et al, Science 2010, Chun et al PNAS 2001) A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir (Pikett et al J Med Virol (ANRS 116 SALTO Study Group))

14 How to control /reduce HIV reservoirs? Reactivation of HIV replication from latent reservoirs: Shock and Kill Courtesy of Nicholas Chomont IL-7 reactivates latent HIV in vitro, also improves HIV-specific immune response but also promotes homeostatic proliferation of HIV latently infected cells (Trono et al, Science) HDAC inhibitors & chromatin modifiers: may reactivate HIV production thereby reducing the pool of latently infected cells (Torno et al, Science) Gar1041 (an experimental leukemia drug) in combination with HAART transiently reduces the proviral DNA reservoir in SIVmac251-infected macaques, (Savarino, Abstract; the IAS HIV Reservoirs Workshop 2010) First encouraging results (Italy) in laboratory and primate model for potential long term remission Purging the Reservoir by Disrupting the PD-1 negative pathway during HAART? (Da Fonseca, Abstract: the IAS HIV Reservoirs Workshop 2010)

15 How to control /reduce HIV reservoirs? Interfering with immunological mechanism that contribute to HIV persistence Other therapeutic interventions (Gene/Mol therapy, ther. vaccine) Courtesy of Nicholas Chomont Reservoir are maintained by Immune regulators such as PD-1 and Ki67 (Da Fonseca, Abstract: the IAS HIV Reservoirs Workshop 2010, Chomont Nat Med 2009) Eramune 02 Therapeutic Vaccine + Integrase Inhibitor + anti-ccr5 (Clinical Trial NCT ) A model for an immune control of the HIV Reservoirs in HLA-B27/57+ LTNPs, (Descours et al, submitted) Targeting pathways downstream of homeostatic proliferation (Chomont et al. Nat Med 2009). Zinc-finger nucleases to disrupt CCR5 in progenitor stem cells - control of HIV in mice (Holt & Cannon: Nature Biotechnology 2010)

16 While we are searching for a cure: Keep patients ready by: Universal Access Early Treatment (Limiting the reservoirs and preserve immune system) Invest in research: Better understanding of biological mechanism and role of the immune system in establishing reservoirs and persistence Better tools and models In vitro and in vivo models More precise assays and sensitive techniques Drug development: increased specificity for latently infected cells Translational Research Inspired from Sharon Lewin, AIDS 2010 Plenary «Strategies for a Cure»

17 Global Scientific Strategy Towards an HIV Cure IAS to coordinate and support the creation of an international multidisciplinary scientific advisory group on HIV Reservoirs to develop a Global Scientific Strategy «Towards an HIV Cure» A Global Scientific Consortium «Towards an (functional) HIV Cure»?

18 The strategic role of the EU Global Scientific Strategy «Towards a (functional) HIV Cure»? Invest in research on HIV reservoirs Include a specific call in FP7 (Coordinated Action?) International HIV Reservoir Research Consortium?

19 Acknowledgements International AIDS Society, Geneva Marie-Capucine Penicaud Tamara Torri Anthony Flynn With courtesy of members of IAS programme committee Towards An HIV Cure who shared their slides: Françoise Barré-Sinousi, Institute Pasteur, Paris, France Nicolas Chomont, Vaccine and Gene Therapy Institute Florida, USA Tae-Wook Chun, National Institutes of Health, USA Alain Lafeuillade, Department of Infectious Diseases, General Hospital, Toulon, France Sharon Lewin, Burnet Institute, Melbourne, Australia

Professor Jonathan Weber

Professor Jonathan Weber HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust

More information

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of

More information

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or

More information

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several

More information

Dr Jintanat Ananworanich

Dr Jintanat Ananworanich BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,

More information

cure research HIV & AIDS

cure research HIV & AIDS Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may

More information

MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure

MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin

More information

T Memory Stem Cells: A Long-term Reservoir for HIV-1

T Memory Stem Cells: A Long-term Reservoir for HIV-1 Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 T Memory Stem Cells: A Long-term Reservoir for HIV-1 Maria J Buzon, PhD Ragon Institute of MGH, MIT and Harvard, Massachussetts General Hospital,

More information

State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP

State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy

More information

Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir

Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir Laura Díaz 1, Carolina Gutiérrez 2, Carmen Page 2, Raquel Lorente 1, Beatriz Hernández-Novoa 2, Alejandro

More information

AIDS free generation. Bob Colebunders Institute of Tropical Medicine

AIDS free generation. Bob Colebunders Institute of Tropical Medicine AIDS free generation Bob Colebunders Institute of Tropical Medicine Why this optimism? Rapid scale-up of antiretroviral therapy Treatment can prevent new infections Expanded coverage of programmes to prevent

More information

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is

More information

GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW

GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW TOWARDS AN CURE PEOPLE FOCUSED SCIENCE DRIVEN JULY 2018 A GLOBAL STRATEGIC APPROACH TOWARDS

More information

Journal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers

Journal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Journal of Infectious Diseases Advance Access published July 11, 2013 1 Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Tae-Wook Chun 1,6, J. Shawn Justement 1, Danielle Murray

More information

Hacia la Curación del VIH

Hacia la Curación del VIH Jornadas 2012 Actualización en Atención Farmacéutica al Paciente Con Patologías Víricas Hacia la Curación del VIH Santiago Moreno Servicio de Enfermedades Infecciosas Hospital Ramón y Cajal Madrid HIV

More information

Advances in HIV science and treatment. Report on the global AIDS epidemic,

Advances in HIV science and treatment. Report on the global AIDS epidemic, HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections

More information

Beyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013

Beyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013 8/5/203 Beyond HAART: Approaches to HIV Eradication I have no financial conflicts of interest to disclose 8 August 203 Adam Spivak MD Visiting Instructor, Division of Infectious Diseases University of

More information

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014

The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014 The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase

More information

HIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS

HIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS HIV Cure Update Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS Financial Disclosures Research grants paid to my institution: Gilead Sciences, Bristol

More information

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of

More information

Pediatric HIV Cure Research

Pediatric HIV Cure Research Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016

More information

Body & Soul. Research update, 25 October 2016

Body & Soul. Research update, 25 October 2016 Body & Soul Research update, 25 October 2016 Updates from BHIVA conference on... Cure breakthrough or not? Long acting retrovirals what do they offer? When to start treatment asap post diagnosis? Media

More information

CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence

CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence IAS 2015 Towards an HIV Cure symposium Vancouver CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence Colleen McGary Paiardini lab Emory University HIV reservoir prevents eradication

More information

UNRAVELING THE MYSTERY BEHIND HIV/AIDS

UNRAVELING THE MYSTERY BEHIND HIV/AIDS PRESS RELEASE 3 MAR 2010 UNRAVELING THE MYSTERY BEHIND HIV/AIDS New findings by Nobel Laureate shed light on the elusive AIDS virus and may lead to effective HIV vaccine development 1. Professor Francoise

More information

5/11/2017. HIV Cure Research Questions and a Few Answers

5/11/2017. HIV Cure Research Questions and a Few Answers HIV Cure Research Questions and a Few Answers Steven G. Deeks, MD Professor of Medicine University of California San Francisco San Francisco, California FORMATTED: 04/13/17 Financial Relationships With

More information

Immunodeficiency. (2 of 2)

Immunodeficiency. (2 of 2) Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related

More information

Invited Review CROI 2018: Advances in Basic Science Understanding of HIV

Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Mario Stevenson, PhD The conference on Retroviruses and Opportunistic Infections represents the most important venue for the dissemination

More information

Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir

Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela

More information

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy We are pleased to announce that the National Institutes of Health (NIH) has awarded nearly $23 million to co-principal

More information

HIV/AIDS Insuring the uninsurable. The future of human longevity: breaking the code Rüschlikon, 8. Nov 2011, Wayne Dam and Urs Widmer

HIV/AIDS Insuring the uninsurable. The future of human longevity: breaking the code Rüschlikon, 8. Nov 2011, Wayne Dam and Urs Widmer HIV/AIDS Insuring the uninsurable The future of human longevity: breaking the code Rüschlikon, 8. Nov 2011, Wayne Dam and Urs Widmer Agenda 30 years AIDS and 15 years HAART biology of HIV (UW) HIV/AIDS

More information

Early Antiretroviral Therapy

Early Antiretroviral Therapy Early Antiretroviral Therapy HIV Cure Research Training Curriculum HIV and Cure Early ART Presented by: Jintanat Ananworanich, MD, PhD June 2016 The HIV CURE research training curriculum is a collaborative

More information

Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD

Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD Conflicts of Interest The pending clinical trials discussed here are funded by grant awards from Gilead

More information

Low-Level Viremia in HIV

Low-Level Viremia in HIV Mountain West AIDS Education and Training Center Low-Level Viremia in HIV Brian R. Wood, MD Medical Director, Mountain West AETC ECHO Telehealth Program Assistant Professor of Medicine, University of Washington

More information

How to best manage HIV patient?

How to best manage HIV patient? How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to

More information

IAS Conference Vienna 18 th to 23 rd July 2010 overview. Paul Clift King s College Hospital/UK-CAB

IAS Conference Vienna 18 th to 23 rd July 2010 overview. Paul Clift King s College Hospital/UK-CAB IAS Conference Vienna 18 th to 23 rd July 2010 overview Paul Clift King s College Hospital/UK-CAB Overall Conference I c. 25,000 participants Covers everything HIV-related Several Pre-conferences: Faith,

More information

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T September 8, 2014 Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV- Infected Subjects Treated with SB-728-T

More information

HIV and transplant: obstacles and opportunities

HIV and transplant: obstacles and opportunities HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part

More information

Clinical HIV-1 eradication studies

Clinical HIV-1 eradication studies Clinical HIV-1 eradication studies Mathias Lichterfeld, M. D., Ph. D. Massachusetts General Hospital Harvard Medical School No disclosures HIV-1 persistence despite HAART Blood Tissue HIV RNA (cps/ml)

More information

HIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016

HIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016 HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk

More information

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University

More information

Management of patients with antiretroviral treatment failure: guidelines comparison

Management of patients with antiretroviral treatment failure: guidelines comparison The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

More information

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies December 11, 2015 Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies Preliminary Data Suggest Adenoviral Delivery Method Superior for Immune Stimulation and Control of Viral

More information

2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?

2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen? Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is

More information

The Road Towards an HIV Cure

The Road Towards an HIV Cure The Road Towards an HIV Cure Authors: Craig McClure and Darien Taylor October 2017 We have done our best to write in plain language. However, an HIV cure treatment glossary may help you to read this article.

More information

HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks

HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA

More information

NIH Public Access Author Manuscript Curr Opin HIV AIDS. Author manuscript; available in PMC 2013 September 05.

NIH Public Access Author Manuscript Curr Opin HIV AIDS. Author manuscript; available in PMC 2013 September 05. NIH Public Access Author Manuscript Published in final edited form as: Curr Opin HIV AIDS. 2013 May ; 8(3): 170 175. doi:10.1097/coh.0b013e32835fc619. How to best measure HIV reservoirs? Christine Rouzioux

More information

TRANS-NIH PLAN FOR HIV RELATED RESEARCH

TRANS-NIH PLAN FOR HIV RELATED RESEARCH National Institutes of Health FY 2018 TRANS-NIH PLAN FOR HIV RELATED RESEARCH Prepared by the Office of AIDS Research Maureen M. Goodenow, Ph.D. NIH Associate Director for AIDS Research and Director, Office

More information

HIV remission after discontinuing ART: is it achievable?

HIV remission after discontinuing ART: is it achievable? HIV remission after discontinuing ART: is it achievable? Jintanat Ananworanich, MD, PhD Associate Director for Therapeutics Research US Military HIV Research Program Maryland, USA jananworanich@hivresearch.org

More information

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis

More information

Targeting latent HIV infection: on the road towards an HIV Cure

Targeting latent HIV infection: on the road towards an HIV Cure Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Targeting latent HIV infection: on the road towards an HIV Cure David M. Margolis, MD Professor of Medicine Treatment Cure Prevention Prevention

More information

Micro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people

Micro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people Micro 301 HIV/AIDS Shiu-Lok Hu hus@uw.edu December 3, 2012 Since its discovery 31 years ago Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people In 2011 34.0 million [31.4 35.9 million]

More information

Approaching a Cure Daniel R. Kuritzkes, MD

Approaching a Cure Daniel R. Kuritzkes, MD Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria

More information

Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX

Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464

More information

Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting

Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis

More information

Professor Brigitte Autran

Professor Brigitte Autran 16 th Annual Resistance and Antiviral Professor Brigitte Autran Centre Hospitalier Universitaire Pitié-Salpétrière, Paris, France Thursday 20 September 2012, Wellcome Collection Conference Centre, London

More information

PERSPECTIVES. Towards an HIV cure: a global scientific strategy

PERSPECTIVES. Towards an HIV cure: a global scientific strategy OPINION Towards an HIV cure: a global scientific strategy The International AIDS Society Scientific Working Group on HIV Cure Abstract Given the limitations of antiretroviral therapy and recent advances

More information

CROI 2016 Review: Immunology and Vaccines

CROI 2016 Review: Immunology and Vaccines Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational

More information

Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia

Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia October 28, 2013 Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks Additional

More information

Can we eradicate HIV?

Can we eradicate HIV? Can we eradicate HIV? New therapeutic strategies towards a cure Laurence COLIN Laboratory of Molecular Virology University of Brussels Belgium The success story of HAART encountered solid barriers to virus

More information

Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know

Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Carolyn K. Burr, EdD, RN Co-Clinical Director Deputy Director François-Xavier Bagnoud Center December 17 th, 2013

More information

HIV cure: current status and implications for the future

HIV cure: current status and implications for the future HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence

More information

The HIV life cycle. integration. virus production. entry. transcription. reverse transcription. nuclear import

The HIV life cycle. integration. virus production. entry. transcription. reverse transcription. nuclear import The HIV life cycle entry reverse transcription transcription integration virus production nuclear import Hazuda 2012 Integration Insertion of the viral DNA into host chromosomal DNA, essential step in

More information

Combined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques

Combined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques Combined and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques Mirko Paiardini Associate Professor, Emory University School of Medicine Yerkes National Primate

More information

The relation between HIV- 1 integration and latency

The relation between HIV- 1 integration and latency The relation between HIV- 1 integration and latency Linos Vandekerckhove HIV translational research, Ghent Department of General Internal Medicine, Infectious Diseases and Psychosomatic Medicine University

More information

Complete Transcriptome Analysis of Latently Infected CD4 + T Cells

Complete Transcriptome Analysis of Latently Infected CD4 + T Cells Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Complete Transcriptome Analysis of Latently Infected CD4 + T Cells Fabio Romerio Institute of Human Virology University of Maryland School

More information

How HIV Causes Disease Prof. Bruce D. Walker

How HIV Causes Disease Prof. Bruce D. Walker How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of

More information

Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir.

Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir. Abstract no. MOLBPEA13 Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir. G. Vansant,,A. Bruggemans, L. Vranckx, S. Saleh, I. Zurnic, F. Christ,

More information

Inves&gación básica y curación del VIH-1

Inves&gación básica y curación del VIH-1 Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion

More information

Module R: Recording the HIV Reservoir

Module R: Recording the HIV Reservoir Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry

More information

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic

More information

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps

More information

Preventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt

Preventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially

More information

BRIEF REPORT METHODS. Twenty-seven HIV-infected individuals receiving ART for a median of 2 years were included in this study (Table 1).

BRIEF REPORT METHODS. Twenty-seven HIV-infected individuals receiving ART for a median of 2 years were included in this study (Table 1). BRIEF REPORT Effect of Histone Deacetylase Inhibitors on HIV Production in Latently Infected, Resting CD4 + T Cells From Infected Individuals Receiving Effective Antiretroviral Therapy Jana Blazkova, 1,a

More information

Introduction to HIV/AIDS

Introduction to HIV/AIDS HIV/AIDS Seminar 5 Welcome Back Introduction to HIV/AIDS History of HIV/AIDS It is now thought that HIV came from a similar virus found in chimpanzees - SIV. HIV probably entered North America around 1970

More information

When to start: guidelines comparison

When to start: guidelines comparison The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count

More information

Partnerships between UNAIDS and the Faith-Based Community

Partnerships between UNAIDS and the Faith-Based Community Partnerships between UNAIDS and the Faith-Based Community Sally Smith- Partnership Adviser. Micah Network: Global Consultation-Churches Living with HIV Pattaya Thailand October 2008 UNAIDS Summary of 2008

More information

Alain Lafeuillade 1*, Assi Assi 1, Cécile Poggi 2, Caroline Bresson-Cuquemelle 3, Eric Jullian 4 and Catherine Tamalet 5

Alain Lafeuillade 1*, Assi Assi 1, Cécile Poggi 2, Caroline Bresson-Cuquemelle 3, Eric Jullian 4 and Catherine Tamalet 5 Lafeuillade et al. AIDS Research and Therapy 2014, 11:33 RESEARCH Open Access Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients

More information

Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection

Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction

More information

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.

More information

Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France

Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France Infection à VIH : une rémission possible Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France Viral reservoirs persist in HIV-infected individuals receiving

More information

Functional cure of HIV: the scale of the challenge. *, David S. Khoury 1

Functional cure of HIV: the scale of the challenge. *, David S. Khoury 1 AnaLysIs Functional cure of HIV: the scale of the challenge Miles P. Davenport 1 *, David S. Khoury 1, Deborah Cromer 1, Sharon R. Lewin 2,3, Anthony D. Kelleher 1 and Stephen J. Kent 2,3,4,5 Abstract

More information

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)

More information

IAS Towards an HIV Cure Symposium. Victoria University City Convention Center, Melbourne, Australia

IAS Towards an HIV Cure Symposium. Victoria University City Convention Center, Melbourne, Australia IAS Towards an HIV Cure Symposium 19 th - 20 th 2014 Victoria University City Convention Center, Melbourne, Australia 19th Saturday 19th 8:30-9:00 Registration Opening 9:00-9:30 Welcome and Introduction

More information

Pathogenesis Update Robert F. Siliciano, MD, PhD

Pathogenesis Update Robert F. Siliciano, MD, PhD Pathogenesis Update Robert F. Siliciano, MD, PhD Professor of Medicine and Molecular Biology and Genetics Johns Hopkins University School of Medicine Investigator, Howard Hughes Medical Institute HIV-1

More information

persistence during therapy Professor of Medicine University of California, San Francisco

persistence during therapy Professor of Medicine University of California, San Francisco The clinical implications of HIV persistence during therapy Steven G. Deeks Professor of Medicine University of California, San Francisco T cell activation declines during long-term HAART, but remains

More information

Inves)gación básica y curación del VIH- 1

Inves)gación básica y curación del VIH- 1 Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT

More information

HIV / AIDS Pathogenesis 2

HIV / AIDS Pathogenesis 2 HIV / AIDS Pathogenesis 2 Henning Drechsler, MD VA North Texas Health Care System UT Southwestern Medical Center Objectives Characterize HIV-1 (classification, structure and life cycle) Describe the clinical

More information

Innovative diagnostics for HIV, HBV and HCV

Innovative diagnostics for HIV, HBV and HCV Innovative diagnostics for HIV, HBV and HCV Dan Otelea National Institute for Infectious Diseases Bucharest, Romania Disclaimer No conflicts of interest Innovative diagnostics for HIV, HBV and HCV - is

More information

How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH

How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH Presentation Outline Big history of global HIV epidemic Current status of HIV and the global AIDS

More information

IAS 2013 Towards an HIV Cure Symposium

IAS 2013 Towards an HIV Cure Symposium Entinostat is a histone deacetylase (HDAC) inhibitor selective for class 1 HDACs and activates HIV production from latently infected primary T-cells Fiona Wightman Monash University, Melbourne, Australia

More information

Professor Anna Maria Geretti

Professor Anna Maria Geretti THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT

More information

JAY A. NELSON, PH.D. Executive Director and Vice President

JAY A. NELSON, PH.D. Executive Director and Vice President JAY A. NELSON, PH.D. Executive Director and Vice President TRANSLATING RESEARCH INTO HEALTH Jay A. Nelson, Ph.D., is the founder and Executive Director of Vaccine & Gene Therapy Institute of Florida (VGTI-FL)

More information

IAS 2013 Towards an HIV Cure Symposium

IAS 2013 Towards an HIV Cure Symposium In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure

More information

Update on HIV Cure Research

Update on HIV Cure Research Update on HIV Cure Research Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland FORMATTED: /7/5 New Orleans, Louisiana: December 5-7,

More information

DNA Genotyping in HIV Infection

DNA Genotyping in HIV Infection Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious

More information

, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic

, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic 1 Two attributes make AIDS unique among infectious diseases: it is uniformly fatal, and most of its devastating symptoms are not due to the causative agent Male to Male sex is the highest risk group in

More information

EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE

EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE CECILE DELILLE LAHIRI, M.D, M.SC ASSISTANT PROFESSOR DIVISION OF INFECTIOUS DISEASES MAY 18, 2016 OUTLINE Describe discrepancy between

More information

Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers

Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers JOURNAL OF VIROLOGY, Sept. 2011, p. 9646 9650 Vol. 85, No. 18 0022-538X/11/$12.00 doi:10.1128/jvi.05327-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Inhibition of HIV-1 Integration

More information

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During

More information

Immuno-modulatory Strategies for Reduction of HIV Reservoir Cells

Immuno-modulatory Strategies for Reduction of HIV Reservoir Cells Immuno-modulatory Strategies for Reduction of HIV Reservoir Cells H.T. Banks, Kevin B. Flores and Shuhua Hu Center for Research in Scientific Computation North Carolina State University Raleigh, NC 27695-8212

More information